Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | Frankfurt | Healthcare | Biotechnology & Medical Research | €117.88B | 31.9x | 1.41 | €462.85 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Regeneron Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €106.87B | 29.9x | -3.69 | €997 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Moderna | Frankfurt | Healthcare | Biotechnology & Medical Research | €43.08B | -7.8x | 0.03 | €110.38 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
argenx | Frankfurt | Healthcare | Biotechnology & Medical Research | €26.99B | -140.6x | -2.25 | €434.20 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Biontech | Frankfurt | Healthcare | Biotechnology & Medical Research | €19.11B | 168.3x | -1.7 | €79 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
BioNTech SE | Xetra | Healthcare | Biotechnology & Medical Research | €19.10B | 167.8x | -1.7 | €79.10 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Qiagen | Xetra | Healthcare | Biotechnology & Medical Research | €8.99B | 28.7x | -5.33 | €40.19 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Qiagen NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.63B | 28.7x | -5.29 | €39.15 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Ascendis Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €7.09B | -12.7x | -1.11 | €123 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Ionis Pharmaceuticals | Frankfurt | Healthcare | Biotechnology & Medical Research | €6.92B | -19.3x | 1.21 | €47.71 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Blueprint Medicines | Frankfurt | Healthcare | Biotechnology & Medical Research | €6.53B | -24x | -0.48 | €104.95 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Exelixis | Frankfurt | Healthcare | Biotechnology & Medical Research | €6.29B | 35.6x | 0.85 | €21.08 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Merus NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €3.31B | -19.8x | -1.41 | €49.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Denali Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €3.17B | -24.8x | -0.33 | €22.10 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Rhythm Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.77B | -10.6x | 0.29 | €45.80 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Morphosys AG | Xetra | Healthcare | Biotechnology & Medical Research | €2.56B | -5.2x | 0.01 | €67.85 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Morphosys | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.56B | -5.2x | 0.01 | €67.75 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
BB Biotech | Xetra | Healthcare | Biotechnology & Medical Research | €2.50B | 7.8x | 0.04 | €45.65 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
BB Biotech | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.50B | 7.8x | 0.04 | €45.50 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Intellia Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.35B | -5x | -20.21 | €23.99 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Iovance Biotherapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.35B | -5.1x | -0.21 | €8.64 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Syndax Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.93B | -7.6x | 0.24 | €22.20 | 4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Evotec AG | Xetra | Healthcare | Biotechnology & Medical Research | €1.55B | -17x | -0.78 | €8.68 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Evotec | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.55B | -17x | -0.78 | €8.74 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Genus | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.43B | 36.6x | -9.78 | €19.80 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Ironwood Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.03B | -1x | 0 | €6.40 | 11.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Viridian Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €973.89M | -3.7x | -0.55 | €14.80 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Formycon | Xetra | Healthcare | Biotechnology & Medical Research | €913.02M | 10.8x | 0.15 | €51.90 | 5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Formycon | Frankfurt | Healthcare | Biotechnology & Medical Research | €913.02M | 10.8x | 0.15 | €51.60 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
CareDx | Frankfurt | Healthcare | Biotechnology & Medical Research | €901.18M | -5.4x | 0.04 | €17.25 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |